Skip to content

BridgeBio Pharma BBIO Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin95.1%-0.7pp95.8%0.0pp95.8%-0.4pp96.2%+0.8pp95.4%-2.9pp
Operating margin-90.5%+13.7pp-104.2%+68.1pp-172.4%+106pp-278.4%+269pp-547.6%-280pp
Net margin-125.9%+20.1pp-146%+81.8pp-227.7%+105pp-332.9%+198pp-531.2%-286pp
Efficiency
Asset turnover0.5×0.0×0.5×+0.1×0.4×+0.2×0.3×+0.1×0.1×-0.2×
Liquidity
Current ratio1.5×-1.2×2.8×-1.1×3.9×-1.3×5.2×+0.6×4.6×-0.1×
Per Share
Book value per share-$11.70-7.4%-$10.89-8.1%-$10.08-7.4%-$9.38-8.2%-$8.67-9.9%
Valuation
Market capitalization$14.4B-2.3%$14.74B+48.5%$9.93B+17.6%$8.44B+28.4%$6.57B+26.8%
Price / sales24.8×-4.5×29.4×+1.3×28.1×-7.7×35.8×-15.8×51.6×+28.2×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are BridgeBio Pharma's profit margins?
BridgeBio Pharma (BBIO) runs a 95.1% gross margin and a -90.5% operating margin, with a -125.9% net margin.
Where do BridgeBio Pharma's ratios come from?
Every ratio is computed from BridgeBio Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.